Business
Opens US Headquarters in San Diego
Opens US Headquarters in San Diego.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 5293Y Scancell Holdings Plc 18 May 2016 \n\n18 May 2016\n \nScancell Holdings Plc\n(\"Scancell\" or the \"Company\")\n \nScancell Opens US Headquarters in San Diego\n \nKey Management Changes to Support Future Growth \n \nScancell Holdings Plc, (AIM:SCLP), today announces the opening of new offices in San Diego to support the Company's ambitious US growth plans together with plans to establish a new base in the Oxford area for its UK corporate and development activities. \n \nIn addition, the following changes have been made to the structure of Scancell's executive management team to optimally align management expertise with the strategic direction outlined in the £6.2m ($9m) fundraising completed in April. \n \nDr John Chiplin, who is based in the US and is currently Scancell's Non-Executive Chairman, will assume the role of Executive Chairman. John will be directly involved in raising the corporate profile of the Company in the US. Recent US transaction experience, as a director/CEO, includes Benitec Biopharma (US IPO), Medistem (acquired by Intrexon), Arana (acquired by Cephalon) and Domantis (acquired by GSK). Prior to Scancell John was CEO of Polynoma, a Phase III cancer vaccine company, based in San Diego.\n \nDr Richard Goodfellow, currently Joint CEO, will become Chief Executive Officer and Professor Lindy Durrant, currently Joint CEO, will become Chief Scientific Officer, allowing her to focus fully on the innovative drug discovery that underpins Scancell's novel technology platforms. \n \nDr Sally Adams will remain as Development Director.\n \nDr John Chiplin, Executive Chairman of Scancell commented: \"The Board believes that these changes align management with the strategic direction outlined at the time of our recent £6m fundraising and optimally leverage expertise with the needs of the Company. Scancell's next generation cancer vaccine platforms, ImmunoBody® and Moditope®, are delivering outstanding results and I am convinced that Scancell will secure wider recognition for its innovative technologies and products in both the United States and Europe over the coming months.\"\n \n-ENDS-\n \nFor Further Information: \n \n\n\n\n\nDr John Chiplin, Executive Chairman\nDr Richard Goodfellow, CEO\n\n\nScancell Holdings Plc\n \n\n...